Cytodyn Inc (CYDY)

[daemon57]

https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciac390/6640219

Extract
TO THE EDITOR—We are grateful for the opportunity to respond to these criticisms regarding our recent report. It is worth first noting that our study was a small exploratory pilot investigation, and we make no claims about treatment efficacy or mechanism but present the data to raise an interesting question about the pathogenesis of long coronavirus disease 2019 (COVID-19) syndrome.

“Responders” were defined as those subjects whose symptoms consistently improved from baseline to the end of the trial. As for any clinically defined syndrome, the symptoms are necessarily interrelated. Symptom collection and scoring followed Food and Drug Administration (FDA) guidance on COVID-19 trials, with final analyses based on qualitative classifications as responder vs nonresponder, thus avoiding quantitative bias due to symptom overlap.

Nonparametric testing was appropriate due to the small sample size and heterogeneity of the syndrome. While there was indeed an increase in percentage of cells expressing CCR5...

Worth reading the extract !!

GLTA REAL LONGS